Literature DB >> 33269683

COVID-19 and Tuberculosis-Related Catastrophic Costs.

Ahmad Fuady1,2, Tanja A J Houweling1, Jan Hendrik Richardus1.   

Abstract

The COVID-19 pandemic has created an unprecedented health crisis and a substantial socioeconomic impact. It also affects tuberculosis (TB) control severely worldwide. Interruptions of many TB control programs because of the COVID-19 pandemic could result in significant setbacks. One of the targets that can be affected is the WHO's End TB Strategy goal to eliminate catastrophic costs of TB-affected households by 2030. Disruptions to TB programs and healthcare services due to COVID-19 could potentially prolong diagnostic delays and worsen TB treatment adherence and outcomes. The economic recession caused by the pandemic could significantly impact household financial capacity because of the reduction of income and the rise in unemployment rates. All of these factors increase the risk of TB incidence and the gravity of economic impact on TB-affected households, and hamper efforts to eliminate catastrophic costs and control TB. Therefore, efforts to eliminate the incidence of TB-affected households facing catastrophic costs will be very challenging. Because financial constraint plays a significant role in TB control, the improvement of health and social protection systems is critical. Even before the pandemic, many TB-high-burden countries (HBCs) lacked robust health and social protection systems. These challenges highlight the substantial need for a more robust engagement of patients and civil society organizations and international support in addressing the consequences of COVID-19 on the control of TB.

Entities:  

Mesh:

Year:  2020        PMID: 33269683      PMCID: PMC7866313          DOI: 10.4269/ajtmh.20-1125

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Adaptations to the first wave of the COVID-19 pandemic by private sector tuberculosis care providers in India.

Authors:  Shamim Mannan; Charity Oga-Omenka; Akhil Soman ThekkePurakkal; Lavanya Huria; Aakshi Kalra; Ravdeep Gandhi; Tunisha Kapoor; Nathali Gunawardena; Shekhar Raj; Manjot Kaur; Angelina Sassi; Tripti Pande; Vijayan Shibu; Sanjay Sarin; Sarabjit Singh Chadha; Petra Heitkamp; Jishnu Das; Raghuram Rao; Madhukar Pai
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-07-19

2.  Call for more investment in cost-effective tuberculosis care.

Authors:  Ahmad Fuady
Journal:  Lancet Reg Health West Pac       Date:  2021-05-13

Review 3.  The impact of COVID-19 on TB: a review of the data.

Authors:  C F McQuaid; A Vassall; T Cohen; K Fiekert; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 2.373

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.